Stocks of CorMedix Inc (NASDAQ:CRMD) traded higher last session on Wall Street, down -6.28% to $6.71.
CRMD stock price is now -36.60% away from the 50-day moving average and -19.02% away from the 200-day moving average. The market capitalization of the company currently stands at $407.14M.
With the price target of $18, Leerink Partners recently initiated with Outperform rating for CorMedix Inc (NASDAQ: CRMD). On January 13, 2025, D. Boral Capital recently initiated its ‘Buy’ rating on the stock quoting a target price of $15, while ‘Rodman & Renshaw’ rates the stock as ‘Buy’
In other news, Mistry Erin, EVP, Chief Commercial Officer bought 1,500 shares of the company’s stock on Oct 31 ’24. The stock was bought for $14,985 at an average price of $9.99. Upon completion of the transaction, the EVP, Chief Commercial Officer now directly owns 52,011 shares in the company, valued at $0.35 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Nov 14 ’24, EVP Hurlburt Elizabeth sold 140,027 shares of the business’s stock. A total of $1,565,670 was realized by selling the stock at an average price of $11.18. This leaves the insider owning 45,397 shares of the company worth $0.3 million. A total of 2.35% of the company’s stock is owned by insiders.
During the past 12 months, CorMedix Inc has had a low of $3.61 and a high of $13.85. As of last week, the company has a debt-to-equity ratio of 0.01, a current ratio of 3.39, and a quick ratio of 3.16. The fifty day moving average price for CRMD is $10.5838 and a two-hundred day moving average price translates $8.2866 for the stock.
The latest earnings results from CorMedix Inc (NASDAQ: CRMD) was released for 2024-12-31. The net profit margin was -41.24% and return on equity was -23.17% for CRMD.
